drugset / Trial / NCT04640038

Contrast Enhanced Ultrasound in COVID-19

NCT04640038

Phase 3 Completed 4 enrolled Children's Hospital of Philadelphia
NaSingle-groupOpen-labelDiagnostic

Summary

Initial data from COVID-19 patients suggests that one of the primary causes of death is significant endothelial injury leading to blood clotting and impaired multiorgan microvascular perfusion. The current study uses a safe, convenient bedside imaging tool called contrast-enhanced ultrasound (CEUS) to estimate the extent of microvascular perfusion impairment in the heart, kidneys and/or brain of COVID-19 pediatric patients in vivo and assess the significance of imaging findings by correlating to clinical outcomes. This pilot study will be conducted at one site, The Children's Hospital of Philadelphia. The investigators plan to enroll and evaluate 30 patients.

Timeline

Start
2020-12-18
Primary completion
2021-09-17
Completion
2021-09-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Lumason Diagnostic / imaging agent 0.03 mg/kg Intravenous